Mechanisms, indications and results of salvage systemic therapy for sporadic and von Hippel-Lindau related hemangioblastomas of the central nervous system

Jody Filippo Capitanio, Elena Mazza, Micaela Motta, Pietro Mortini, Michele Reni

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Hemangioblastomas (HBs) are rare indolent vascular tumors that may occur sporadically or in association with von Hippel-Lindau (VHL) disease. Total neurosurgical resection is the standard upfront approach providing long-term tumor control. At time of tumor recurrence, second surgery, radiosurgery or radiotherapy are the main therapeutic strategies.Limited information is available on the role of pharmacological strategies. Anti-angiogenic agents, particularly multitarget tyrosine kinase inhibitors (semaxanib, sunitinib, vatalanib), thalidomide and interferon alfa-2a are currently the most widely studied strategies to prolonge disease stability.Salvage therapy with anti-angiogenetic drugs may be of benefit in some patients who are not suitable for surgery, radiosurgery or radiotherapy, with progressive or recurrent hemangioblastoma especially those located in retina, since anti-angiogenetic therapy may delay tumor progression. This strategy warrants prospective evaluation in a clinical trial.

Original languageEnglish
Pages (from-to)69-84
Number of pages16
JournalCritical Reviews in Oncology/Hematology
Volume86
Issue number1
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Hemangioblastoma
Salvage Therapy
Central Nervous System
Radiosurgery
Neoplasms
Radiotherapy
von Hippel-Lindau Disease
Thalidomide
Protein-Tyrosine Kinases
Blood Vessels
Retina
Clinical Trials
Pharmacology
Recurrence
Therapeutics
Pharmaceutical Preparations

Keywords

  • Anti-angiogenetic drugs
  • Guidelines
  • HB follow-up
  • Interferon-alpha-2a
  • Pharmacologic treatment for HBs
  • Salvage systemic therapy
  • Semaxanib
  • Sporadic HB
  • Su5416
  • Thalidomide
  • Therapeutic options
  • Tyrosine kinase inhibitors
  • Vatalanib
  • VHL related HB

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

@article{ca3c645c927643f5956a3fe6115e5880,
title = "Mechanisms, indications and results of salvage systemic therapy for sporadic and von Hippel-Lindau related hemangioblastomas of the central nervous system",
abstract = "Hemangioblastomas (HBs) are rare indolent vascular tumors that may occur sporadically or in association with von Hippel-Lindau (VHL) disease. Total neurosurgical resection is the standard upfront approach providing long-term tumor control. At time of tumor recurrence, second surgery, radiosurgery or radiotherapy are the main therapeutic strategies.Limited information is available on the role of pharmacological strategies. Anti-angiogenic agents, particularly multitarget tyrosine kinase inhibitors (semaxanib, sunitinib, vatalanib), thalidomide and interferon alfa-2a are currently the most widely studied strategies to prolonge disease stability.Salvage therapy with anti-angiogenetic drugs may be of benefit in some patients who are not suitable for surgery, radiosurgery or radiotherapy, with progressive or recurrent hemangioblastoma especially those located in retina, since anti-angiogenetic therapy may delay tumor progression. This strategy warrants prospective evaluation in a clinical trial.",
keywords = "Anti-angiogenetic drugs, Guidelines, HB follow-up, Interferon-alpha-2a, Pharmacologic treatment for HBs, Salvage systemic therapy, Semaxanib, Sporadic HB, Su5416, Thalidomide, Therapeutic options, Tyrosine kinase inhibitors, Vatalanib, VHL related HB",
author = "Capitanio, {Jody Filippo} and Elena Mazza and Micaela Motta and Pietro Mortini and Michele Reni",
year = "2013",
month = "4",
doi = "10.1016/j.critrevonc.2012.10.001",
language = "English",
volume = "86",
pages = "69--84",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Mechanisms, indications and results of salvage systemic therapy for sporadic and von Hippel-Lindau related hemangioblastomas of the central nervous system

AU - Capitanio, Jody Filippo

AU - Mazza, Elena

AU - Motta, Micaela

AU - Mortini, Pietro

AU - Reni, Michele

PY - 2013/4

Y1 - 2013/4

N2 - Hemangioblastomas (HBs) are rare indolent vascular tumors that may occur sporadically or in association with von Hippel-Lindau (VHL) disease. Total neurosurgical resection is the standard upfront approach providing long-term tumor control. At time of tumor recurrence, second surgery, radiosurgery or radiotherapy are the main therapeutic strategies.Limited information is available on the role of pharmacological strategies. Anti-angiogenic agents, particularly multitarget tyrosine kinase inhibitors (semaxanib, sunitinib, vatalanib), thalidomide and interferon alfa-2a are currently the most widely studied strategies to prolonge disease stability.Salvage therapy with anti-angiogenetic drugs may be of benefit in some patients who are not suitable for surgery, radiosurgery or radiotherapy, with progressive or recurrent hemangioblastoma especially those located in retina, since anti-angiogenetic therapy may delay tumor progression. This strategy warrants prospective evaluation in a clinical trial.

AB - Hemangioblastomas (HBs) are rare indolent vascular tumors that may occur sporadically or in association with von Hippel-Lindau (VHL) disease. Total neurosurgical resection is the standard upfront approach providing long-term tumor control. At time of tumor recurrence, second surgery, radiosurgery or radiotherapy are the main therapeutic strategies.Limited information is available on the role of pharmacological strategies. Anti-angiogenic agents, particularly multitarget tyrosine kinase inhibitors (semaxanib, sunitinib, vatalanib), thalidomide and interferon alfa-2a are currently the most widely studied strategies to prolonge disease stability.Salvage therapy with anti-angiogenetic drugs may be of benefit in some patients who are not suitable for surgery, radiosurgery or radiotherapy, with progressive or recurrent hemangioblastoma especially those located in retina, since anti-angiogenetic therapy may delay tumor progression. This strategy warrants prospective evaluation in a clinical trial.

KW - Anti-angiogenetic drugs

KW - Guidelines

KW - HB follow-up

KW - Interferon-alpha-2a

KW - Pharmacologic treatment for HBs

KW - Salvage systemic therapy

KW - Semaxanib

KW - Sporadic HB

KW - Su5416

KW - Thalidomide

KW - Therapeutic options

KW - Tyrosine kinase inhibitors

KW - Vatalanib

KW - VHL related HB

UR - http://www.scopus.com/inward/record.url?scp=84875056306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875056306&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2012.10.001

DO - 10.1016/j.critrevonc.2012.10.001

M3 - Article

C2 - 23148943

AN - SCOPUS:84875056306

VL - 86

SP - 69

EP - 84

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -